EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Baseline circulating tumour DNA and total metabolic tumour volume as early outcome predictors in aggressive large B‐cell lymphoma. A real‐world 112‐patient cohort

Enora Le Goff iD, Paul Blanc-Durand, Louise Roulin, Charlotte Lafont, Romain Loyaux, Diana-Laure MBoumbae, Ichrafe Benmaad, Alexis Claudel, Elsa Poullot, Cyrielle Robe, Guillaume Gricourt, Abdelrazak Aissat und 6 weitere

British Journal of Haematology · 2023-07 · 202 (1) · 54-64

DOI: 10.1111/bjh.18809 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift British Journal of Haematology, online erschienen am 10.04.2023. Verfasst von Enora Le Goff und 17 weiteren Autor:innen. Beteiligte Einrichtung: Lymphoid Malignancies Unit, Assistance Publique des Hôpitaux de Paris, HU Henri Mondor, Créteil, France. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Approximately 20%–50% of patients with large B‐cell lymphoma (LBCL) experience poor outcomes. We aimed to evaluate the combined prognostic value of circulating tumour DNA (ctDNA) and total metabolic tumour volume (TMTV) in LBCL. This observational single‐centre study included 112 newly diagnosed LBCL patients, receiving R‐CHOP/R‐CHOP‐like chemotherapies. CtDNA load was calculated following next‐generation sequencing of cell‐free DNA (cfDNA) using a targeted 40‐gene lymphopanel. TMTV was measured using a fully automated artificial intelligence‐based method for lymphoma lesion segmentation. CtDNA was detected in cfDNA samples from 95 patients with a median concentration of 3.15 log haploid genome equivalents per mL. TMTV measurements were available for 102 patients. The median TMTV was 501 mL. High ctDNA load (>3.57 log hGE/mL) or high TMTV (>200 mL) were associated with shorter 1‐year PFS (44% vs. 83%, p < 0.001 and 64% vs. 97%, p = 0.002, respectively). When combined, three prognostic groups were identified. The shortest PFS was observed when both TMTV and ctDNA load were high ( p < 0.001). Even with a short follow up, combining ctDNA load with TMTV improved the risk stratification of patients with aggressive LBCL. In the near future, very high‐risk patients could benefit from CAR T‐cell therapy or bispecific antibodies as first‐line treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Circulating Tumor DNALymphoma, Large B-Cell, DiffuseHumansTumor BurdenArtificial IntelligencePrognosisFluorodeoxyglucose F18Positron Emission Tomography Computed TomographyRetrospective Studies

Stichwörter der Autor:innen

circulating tumour DNAneoplasm stagingnon-Hodgkin lymphomapositron emission tomography computed tomographyprognosis

Substanzen

Circulating Tumor DNAFluorodeoxyglucose F18

Autor:innen und Institutionen

  • Lymphoid Malignancies Unit, Assistance Publique des Hôpitaux de Paris, HU Henri Mondor, Créteil, France.
  • Nuclear Medicine Department, Assistance Publique des Hôpitaux de Paris, HU Henri Mondor, Créteil, France.
  • Paris-Est Créteil University, INSERM, IMRB, F-94010, Créteil, France.
  • Public Health Department, Assistance Publique des Hôpitaux de Paris, HU Henri Mondor, Créteil, France.
  • Hematobiology and Immunobiology Department, Assistance Publique des Hôpitaux de Paris, HU Henri Mondor, Créteil, France.
  • Pathology Department, Assistance Publique des Hôpitaux de Paris, HU Henri Mondor, Créteil, France.

ORCID-Profile: Enora Le Goff, Marie-Helene Delfau-Larue

Zitieren

APA

Le Goff, E., Blanc-Durand, P., Roulin, L., Lafont, C., Loyaux, R., MBoumbae, D. L., Benmaad, I., Claudel, A., Poullot, E., Robe, C., Gricourt, G., Aissat, A., Copie-Bergman, C., Lemonnier, F., Gaulard, P., Itti, E., Haioun, C., & Delfau-Larue, M. H. (2023). Baseline circulating tumour DNA and total metabolic tumour volume as early outcome predictors in aggressive large B‐cell lymphoma. A real‐world 112‐patient cohort. British Journal of Haematology, 202(1), 54-64. https://doi.org/10.1111/bjh.18809

Vancouver

Le Goff E, Blanc-Durand P, Roulin L, Lafont C, Loyaux R, MBoumbae DL, et al. Baseline circulating tumour DNA and total metabolic tumour volume as early outcome predictors in aggressive large B‐cell lymphoma. A real‐world 112‐patient cohort. British Journal of Haematology. 2023;202(1):54-64. doi:10.1111/bjh.18809

BibTeX
@article{LeGoff2023,
  author = {Le Goff, Enora and Blanc-Durand, Paul and Roulin, Louise and Lafont, Charlotte and Loyaux, Romain and MBoumbae, Diana-Laure and Benmaad, Ichrafe and Claudel, Alexis and Poullot, Elsa and Robe, Cyrielle and Gricourt, Guillaume and Aissat, Abdelrazak and Copie-Bergman, Christiane and Lemonnier, François and Gaulard, Philippe and Itti, Emmanuel and Haioun, Corinne and Delfau-Larue, Marie-Helene},
  title = {Baseline circulating tumour DNA and total metabolic tumour volume as early outcome predictors in aggressive large B‐cell lymphoma. A real‐world 112‐patient cohort},
  journal = {British Journal of Haematology},
  year = {2023},
  volume = {202},
  number = {1},
  pages = {54--64},
  doi = {10.1111/bjh.18809}
}
Kostenlos starten →